Organizations shaping AI

Generate:Biomedicines

Biotechnology company developing protein therapeutics through an integrated platform that combines machine learning, biological engineering, and automated experimentation.

AI drug-discovery company (Genesis Therapeutics) in the San Francisco Bay Area, whose GEMS platform combines deep learning and physics-based simulation for small-molecule discovery.

GRAIL is a healthcare company developing multi-cancer early-detection blood tests. Its Galleri test uses signals in blood to screen for many cancer types, making the company part of the wider computational biology and diagnostics landscape around large-scale health data.

Global biopharmaceutical company focused on vaccines, specialty medicines, and general medicines.

insitro

Drug-discovery company applying machine learning to biology, founded by Daphne Koller.

AI drug-discovery company launched in 2025 by Reid Hoffman (co-founder of LinkedIn) and oncologist Siddhartha Mukherjee. Uses generative chemistry and biology to develop new medicines, beginning with cancer.

Contract research organization providing drug discovery and development services to biopharmaceutical companies.

Biotechnology company developing diagnostics and drug programs for persistent microbial infections implicated in chronic disease.

Seattle-based health-AI startup, co-founded by Leon Gatys, building a biomedical foundation model that predicts health outcomes from smartphone and wearable signals.

Profluent

AI-for-biology company founded by Ali Madani, formerly of Salesforce Research. Trains generative protein language models for programmable biology; released OpenCRISPR-1, the first AI-designed, open-source gene editor.

Recursion

Recursion Pharmaceuticals is an AI drug-discovery company headquartered in Salt Lake City founded by Chris Gibson and others. It pairs automated cell imaging with machine learning to identify drug candidates (NASDAQ: RXRX).

Reliant AI was a biopharma analytics startup with operations in Montreal and Berlin, founded by former Google DeepMind leaders and launched out of stealth in 2024. It was acquired by Cohere in May 2026 to expand into life sciences.

Rockefeller University is a graduate biomedical research university in New York City as the Rockefeller Institute for Medical Research. It is focused on biological and medical science, with doctoral and postdoctoral training and a long record of basic-science discoveries.

Biopharmaceutical company formed from Sosei Group and Heptares Therapeutics, specialising in structure-based drug discovery targeting GPCRs.

Unlearn.AI is a San Francisco-based company founded by Charles Fisher that creates AI-generated "digital twins" of clinical-trial participants, enabling trials with smaller control groups.

UK-based think tank and research organization focused on aging, longevity, and biogerontology.

Toronto-based biotech company, founded in 2014 by Brendan Frey, applying deep learning to genomic medicine.

Deepcell combines high-resolution imaging, microfluidics and machine learning to identify and sort cells by their visible morphology. Its platform lets biologists isolate cells without relying only on molecular labels and creates data for downstream research.

Generative-AI biotech startup founded by Namrata Anand (Y Combinator W23), building AI software for protein design.